Stem cell trial shows potential to rebuild bone in osteoporosis patients

A Phase 1 clinical trial has demonstrated that modified mesenchymal stem cells may help rebuild bone in patients with advanced osteoporosis. The study, published in the journal Cell in September 2026, involved 10 women who received a single intravenous infusion of their own bone marrow cells that had been laboratory-modified to improve their ability to navigate to skeletal sites.

While the primary goal of the trial was to assess safety and feasibility, researchers observed a significant reduction in fractures. Before the treatment, the participants averaged eight fractures per year; following the infusion, that number dropped to an average of 0.5 fractures per year. Imaging and bone samples also indicated signs of new bone formation.

Despite these promising early results, researchers cautioned that the study was small and lacked a placebo group. Larger clinical trials are required to confirm whether this method can effectively prevent fractures and serve as a viable treatment for the millions of people affected by the disease.